First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer

作者
Ryan Joseph Sullivan,Oladapo Yeku,Deanna K. Teoh,Shilpa Gupta,Daniela Elena Matei,Andressa S. Laino,Jing Sun,Lili Zhu,Linh M. Van,Stéphanie Pascarella,Sima J. Zacharek,Khanh T Do,Antonio Jimeno
出处
期刊:Oncologist [AlphaMed Press]
卷期号:30 (6) 被引量:19
标识
DOI:10.1093/oncolo/oyaf115
摘要

BACKGROUND: mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity, thus mRNA-2416 plus ICI may potentiate antitumor activity. METHODS: This first-in-human, phase I/II, open-label, multicenter study examined the safety, tolerability, and efficacy of mRNA-2416 alone (arm A) or with durvalumab (arm B) in patients with advanced solid tumors or lymphoma (NCT03323398). Phase I primary objectives included assessment of safety/tolerability and maximum tolerated dose (MTD)/recommended dose for expansion; phase II arm B dose expansion assessed objective response rate in ovarian cancers. Secondary objectives included pharmacokinetics, disease control rate, duration of response, and progression-free survival (PFS). Assessments of immunologic response to treatment were exploratory. RESULTS: From August 2017 to August 2021, 79 patients were enrolled; 61 received treatment (arm A: 39, arm B: 22), including 16 in the expansion cohort. MTD was not reached. Treatment-related emergent adverse events were primarily grade 1/2, with 8 grade 3 and no grade 4/5 events. On-treatment tumor biopsies demonstrated increased OX40L protein expression, elevated PD-L1, and proinflammatory responses. Tumor shrinkage occurred in injected and surrounding non-injected tumors. Median (95% CI) PFS was 60.0 (50.0 to 108.0) and 50.0 (38.0 to 55.0) days for arms A and B, respectively. CONCLUSIONS: mRNA-2416 alone or with durvalumab was well tolerated. Pharmacodynamic analyses support Itu mRNA proof-of-concept. Predefined primary efficacy endpoints were not met in an exploratory cohort of ovarian cancer. Additional research is warranted to further inform this therapeutic approach.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
cw完成签到,获得积分10
1秒前
1秒前
懒得想发布了新的文献求助10
2秒前
3123939715发布了新的文献求助10
2秒前
3秒前
5秒前
shisheng发布了新的文献求助10
5秒前
6秒前
6秒前
7秒前
共享精神的应助被科研通管家采纳,获得10
7秒前
所所的应助被yyy采纳,获得10
8秒前
IDCY的应助被科研通管家采纳,获得30
8秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
8秒前
田様的应助被科研通管家采纳,获得10
8秒前
大个的应助被科研通管家采纳,获得10
8秒前
追寻如萱发布了新的文献求助10
8秒前
8秒前
传奇3的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
9秒前
9秒前
wzm完成签到,获得积分10
10秒前
10秒前
一只大嵩鼠完成签到 ,获得积分10
11秒前
11秒前
研友_ndo39L发布了新的文献求助10
11秒前
11秒前
12秒前
喜羊羊发布了新的文献求助10
12秒前
初景的应助被吴佳欣采纳,获得20
12秒前
幸运的风完成签到,获得积分10
13秒前
14秒前
小甜发布了新的文献求助10
15秒前
fffF发布了新的文献求助10
16秒前
马小跳发布了新的文献求助50
16秒前
欢呼采枫完成签到 ,获得积分10
16秒前
香蕉千风完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178695
求助须知:如何正确求助?哪些是违规求助? 9569449
关于积分的说明 21804643
捐赠科研通 7773744
什么是DOI,文献DOI怎么找? 3432903
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478500